CCR2 and metabolic dysfunction-associated steatohepatitis: Recent studies have demonstrated that pharmacological inhibition of CCR2 by CVC decreases hepatic steatosis and fibrosis 15, 25, 26 Furthermore, CCR2 inhibition by CVC can improve insulin resistance and steatohepatitis in NASH patients.27, 28 Whether CVC can also improve liver fibrosis in other models remains unknown.